SUMMARY A 68 year old man with rheumatoid arthritis developed marrow aplasia during D-penicillamine treatment. Recovery of granulopoiesis and erythropoiesis was ineffective with features of a secondary sideroblastic anaemia. Absence of megakaryopoiesis persisted. Therapeutic measures failed, and the patient finally died. These events illustrate a haematopoietic stem cell injury induced by D-penicillamine.
occurrence of adverse effects, some of which are potentially hazardous.4 Haematological toxicity is the most serious of the untoward effects which may be produced.2 5 Fatal reactions are associated predominantly with bone marrow aplasia. Of the 18 deaths associated with D-penicillamine treatment reported to the Committee on Safety of Medicines in the UK between January 1964 and December 1977, 14 were due to blood dyscrasias, half of them marrow aplasia.5
As far as sideroblastic anaemia is concerned no case reports have so far been published about this effect during the use of D-penicillamine in the treatment of rheumatoid arthritis. In the treatment of primary biliary cirrhosis with 1000 mg Dpenicillamine daily for one year, however, sideroblastic anaemia has been noted. 6 We report a case of acquired sideroblastic anaemia which evolved after a phase of bone Acceptcd for publication 24 Junc 1986. Corrcspondcncc to Dr J W J Bijisma. A postmortem examination showed that the bone marrow was hypercellular with a relative plasmacytosis and the presence of many ring sideroblasts. Necropsy also disclosed diffuse bronchopneumonia and destruction of several lumbar vertebrae due to osteomyelitis, probably caused by the infection with P mirabilis.
Discussion
Thrombocytopenia.ineutropenia, and proteinuria are frequently observed side effects of D-penicillamine, which require frequent surveillance with blood and urine checks. It is our policy to perform complete blood couints including platelet counts everx two weeks for the first six months aind monthlx thereafter. Patients are atlerted to the need for this surveillance but sometimes omit tO xisit the outpatient clinic.
This patient dex eloped a bone marrow aplasia seven months after starting D-penicillarmine treatment. The total dose of 1)-penicillarmine at that time was 81 g (mean dose 36() mg/day). We consider this aplasila to have beeni induced by i)-penicillamine since this drug has definitely beeii associated with aplastic -anaemia.. The risk of haernatological toxicity associated xith indomnethacin is xerx loxV. 
